title: Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China.
abstract: Loss of p53 function compromises genetic homeostasis, which induces deregulated DNA replication, damages DNA, and subsequently results in increased resistance to anticancer agents. Pharmacological approaches using recombinant adenoviruses (Ad) have been developed to restore the p53 functions. Another approach for gene medicine is to modify Ad replication in a tumor-specific manner, which induces tumor cell death without damaging normal tissues in the vicinity. The Ad-derived gene medicines, Ad expressing the wild-type p53 gene and replication-competent Ad defective of the E1B-55kDa gene, have been tested for their clinical feasibility and became commercially available in China. These agents demonstrated their antitumor activities as a monotherapy and in combination with conventional chemotherapeutic agents. In this article, we summarize the outcomes of clinical trials in China, most of which have been published in domestic Chinese journals, and discuss potential directions of cancer gene therapy with these agents.
authors.affiliation: Division of Pathology, Chiba Cancer Center Research Institute, 666-1 Nitona, Chuo-ku, Chiba, Japan.
authors.forename: Guangyu
authors.initials: G
authors.lastname: Ma
authors.forename: Hideaki
authors.initials: H
authors.lastname: Shimada
authors.forename: Kenzo
authors.initials: K
authors.lastname: Hiroshima
authors.forename: Yuji
authors.initials: Y
authors.lastname: Tada
authors.forename: Nobuo
authors.initials: N
authors.lastname: Suzuki
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Tagawa